BLACK DIAMOND THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
BLACK DIAMOND THERAPEUTICS, INC. (BDTX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period of 1.04 million shares for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-08.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod · last filed 2022-11-08
- BLACK DIAMOND THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2022-09-30 was 351.26K shares, a 4.17% increase year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2022-06-30 was 343.50K shares, a 778.61% increase year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2022-03-31 was 347.83K shares, a 2023.89% increase year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2021-12-31 was 342.24K shares, a 34223600.00% increase year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2021 was 734.93K shares, a 1748.22% increase from fiscal 2020.
- BLACK DIAMOND THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2020 was 39.76K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month |
|---|---|---|---|---|
| 2022-09-30 | 351.26K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | 694.76K shares derived: sum of 2 quarters · filed 2022-11-08 | 1.04M shares 10-Q · filed 2022-11-08 | 1.38M shares derived: sum of 4 quarters · filed 2022-11-08 |
| 2022-06-30 | 343.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | 691.33K shares 10-Q · filed 2022-08-09 | 1.03M shares derived: sum of 3 quarters · filed 2022-08-09 | 1.37M shares derived: sum of 4 quarters · filed 2022-08-09 |
| 2022-03-31 | 347.83K shares 10-Q · filed 2022-05-11 | 690.07K shares derived: sum of 2 quarters · filed 2022-05-11 | 1.03M shares derived: sum of 3 quarters · filed 2022-05-11 | 1.07M shares derived: sum of 4 quarters · filed 2022-05-11 |
| 2021-12-31 | 342.24K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | 679.46K shares derived: sum of 2 quarters · filed 2022-03-17 | 718.55K shares derived: sum of 3 quarters · filed 2022-03-17 | 734.93K shares 10-K · filed 2022-03-17 |
| 2021-09-30 | 337.22K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | 376.31K shares derived: sum of 2 quarters · filed 2021-11-08 | 392.69K shares 10-Q · filed 2021-11-08 | 392.69K shares derived: sum of 4 quarters · filed 2021-11-08 |
| 2021-06-30 | 39.10K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | 55.47K shares 10-Q · filed 2021-08-12 | 55.47K shares derived: sum of 3 quarters · filed 2021-08-12 | 55.47K shares derived: sum of 4 quarters · filed 2021-08-12 |
| 2021-03-31 | 16.38K shares 10-Q · filed 2021-05-07 | 16.38K shares derived: sum of 2 quarters · filed 2021-05-07 | 16.38K shares derived: sum of 3 quarters · filed 2021-05-07 | 18.67K shares derived: sum of 4 quarters · filed 2021-05-07 |
| 2020-12-31 | 1.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | 1.00 shares derived: sum of 2 quarters · filed 2021-03-25 | 2.29K shares derived: sum of 3 quarters · filed 2021-03-25 | 39.76K shares 10-K · filed 2021-03-25 |
| 2020-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | 2.29K shares derived: sum of 2 quarters · filed 2020-11-10 | 39.76K shares 10-Q · filed 2020-11-10 | |
| 2020-06-30 | 2.29K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | 39.76K shares 10-Q · filed 2020-08-11 | ||
| 2020-03-31 | 37.48K shares 10-Q · filed 2020-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |